广州润生细胞医药科技有限责任公司招聘

Guangzhou Runsheng Cytomed Technology Co., Ltd. is a Sino-foreign joint venture biotechnology enterprise dedicated to cell medicine R&D and clinical translational research. The founder and academic leader of the company, Professor Ruan Runsheng, holds a postdoctoral degree from the University of Zurich in Switzerland, is a senior researcher at the National University of Singapore's Department of Medicine, a chief researcher at the Institute of Bioengineering and Nanotechnology of the Singapore Science and Technology Agency, and a member of the European Society of Medical Oncology (ESMO). He has also been included in the US New Century 500 Scientists and the Marquis' Who's Who Yearbook of the United States. Professor Ruan Runsheng has long been committed to the research and development of cellular immunology, with his latest achievement being the Tvac？ tumor personalized precision combined immunotherapy technology.

Founded on September 24, 2019, in Nansha, Guangzhou, the company focuses on exploring and developing the clinical applications of Tvac？ tumor personalized precision combined immunotherapy technology. This technology uses genomics, proteomics, and other omics technologies along with tumor immunology to achieve individualized precision treatment, marking an important direction for future cancer treatments.

Currently, the company has established four platforms: bioinformatics, proteomics, peptide synthesis, and cellular immunity. These platforms are equipped with high-speed local servers and cloud platforms, ultra-high-throughput 106-channel peptide synthesizers, liquid mass spectrometers, PCR instruments, Elispot, flow cytometers, RTCA, and cell culture rooms. These advanced facilities ensure robust support for the screening of new antigens and the development of peptide drugs. The company has built a highly specialized technical R&D team leveraging its platform advantages. Core team members come from prestigious institutions such as the Hong Kong University of Science and Technology, Technical University of Denmark, Stanford University School of Medicine, Harvard Medical School, and Macquarie University in Australia, all holding master's or doctoral degrees. Their expertise spans molecular biology, biochemistry, tumor immunology, clinical medicine, and industrialization.

The company has established strategic partnerships with institutions such as the National University Hospital of Singapore, Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center, the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou Medical College, Guangdong Provincial People's Hospital, and Guangzhou First People's Hospital. Tvac？ technology is undergoing steady clinical trials, with smooth progress. Plans are underway to submit an NDA for Tvac？ within the next three years, aiming for formal clinical application in tumor treatment. Simultaneously, the company is advancing other tumor cell therapy R&D and clinical translation projects.

In 2021, the company partnered with the Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center to establish a postdoctoral research station, continuously attracting and nurturing high-end biomedical talent. It aims to provide a platform for international researchers pursuing the dream of medical practice.

The company is currently staffed primarily by R&D personnel, with two foreign experts, and maintains a flexible organizational structure and fresh corporate culture. It is a dynamic and energetic cell medicine R&D team with international vision and top-tier standards. Moving forward, the company will closely align with market demands, applying professional technology to medical institutions and patients, and creating an innovative technology platform that integrates scientific development, talent cultivation, and shared benefits.